{"id":40100,"date":"2025-07-28T11:14:47","date_gmt":"2025-07-28T09:14:47","guid":{"rendered":"https:\/\/www.ipsen.com\/it\/?post_type=press_release&p=40100"},"modified":"2025-07-28T11:29:12","modified_gmt":"2025-07-28T09:29:12","slug":"oncologia-cabozantinib-approvato-in-europa-nei-tumori-neuroendocrini-avanzati-nets-precedentemente-trattati","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/it\/press-releases\/oncologia-cabozantinib-approvato-in-europa-nei-tumori-neuroendocrini-avanzati-nets-precedentemente-trattati\/","title":{"rendered":"Oncologia: Cabozantinib approvato in Europa nei tumori neuroendocrini avanzati (NETs) precedentemente trattati"},"content":{"rendered":"\n